Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M, Lachaud C, Lopes R, Kuchcinski G, Auger F, Kyheng M, Duhamel A, Pérez T, Pradat PF, Blasco H, Veyrat-Durebex C, Corcia P, Oeckl P, Otto M, Dupuis L, Garçon G, Defebvre L, Cabantchik ZI, Duce J, Bordet R, Devos D. Moreau C, et al. Among authors: cabantchik zi. Antioxid Redox Signal. 2018 Sep 10;29(8):742-748. doi: 10.1089/ars.2017.7493. Epub 2018 Feb 8. Antioxid Redox Signal. 2018. PMID: 29287521 Free PMC article. Clinical Trial.
Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R. Devos D, et al. Among authors: cabantchik zi. Antioxid Redox Signal. 2014 Jul 10;21(2):195-210. doi: 10.1089/ars.2013.5593. Epub 2014 Feb 6. Antioxid Redox Signal. 2014. PMID: 24251381 Free PMC article. Clinical Trial.
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC; FAIRPARK-II and FAIRALS-II studygroups. Devos D, et al. Among authors: cabantchik zi. J Neural Transm (Vienna). 2020 Feb;127(2):189-203. doi: 10.1007/s00702-019-02138-1. Epub 2020 Jan 7. J Neural Transm (Vienna). 2020. PMID: 31912279 Free article. Review.
Iron as a therapeutic target for Parkinson's disease.
Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Moreau C, et al. Among authors: cabantchik zi. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Mov Disord. 2018. PMID: 29380903 Review. No abstract available.
Iron chelation therapy.
Hershko CM, Link GM, Konijn AM, Cabantchik ZI. Hershko CM, et al. Among authors: cabantchik zi. Curr Hematol Rep. 2005 Mar;4(2):110-6. Curr Hematol Rep. 2005. PMID: 15720959
Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. Boddaert N, et al. Among authors: cabantchik zi. Blood. 2007 Jul 1;110(1):401-8. doi: 10.1182/blood-2006-12-065433. Epub 2007 Mar 22. Blood. 2007. PMID: 17379741 Free article. Clinical Trial.
169 results